74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Illumina Inc
Open
SectorHealthcare
131.7 1.21
Overview
Share price change
24h
Min
129.31
Max
133.11
Income | 184M 334M |
|---|---|
Sales | 76M 1.2B |
P/E Sector Avg | 23.439 66.418 |
Profit margin | 28.818 |
Employees | 8,600 |
EBITDA | 108M 445M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +7.38% upside |
Next Earnings | 30 Apr 2026 |
|---|
Market Cap | -2.2B 20B |
|---|---|
Previous open | 130.49 |
Previous close | 131.7 |
News Sentiment
By Acuity
11%
89%
12 / 348 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Illumina Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Illumina Inc Forecast
Price Target
By TipRanks
7.38% upside
12 Months Forecast
Average 136.33 USD 7.38%
High 170 USD
Low 85 USD
Based on 11 Wall Street analysts offering 12 month price targets forIllumina Inc - Dist in the last 3 months.
Sentiment
By Acuity
12 / 348 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Illumina Inc
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
Live chat